Circulating cytokine levels and 5-year vascular recurrence after stroke: a multicenter prospective cohort study

Lanyue Zhang[1]*, Mohamad Ali Antabi[1]*, Jana Mattar[1], Omar El Bounkari[1], Rong Fang[1], Karin Waegemann[1, 2], Felix J. Bode[3, 4], Sebastian Stösser[3, 4], Peter Hermann[5, 6], Thomas G. Liman[7-9], Christian H. Nolte[8, 10, 11], Benno Ikenberg[12], Kathleen Bernkopf[12], Wenzel Glanz[13, 14], Daniel Janowitz[1], Annika Spottke[3, 4], Michael Wolfgang Görtler[13,14], Silke Wunderlich[12], Inga Zerr[5, 6]; Gabor C. Petzold[3, 4], Matthias Endres[7, 8, 11, 15, 16], Jürgen Bernhagen[1, 17, 18], Martin Dichgans[1, 2, 17, 18], Marios K. Georgakis[1, 18, 19] on behalf of the DEMDAS investigators[#]

[1] Institute for Stroke and Dementia Research (ISD), LMU University Hospital, LMU Munich, Munich, Germany

[2] German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

[3] German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

[4] Department of Vascular Neurology, University Hospital Bonn, Bonn, Germany

[5] Department of Neurology, University Medical Center Göttingen, Göttingen, Germany

[6] German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany

[7] Center for Stroke Research Berlin (CSB), Charité - Universitätsmedizin Berlin

[8] German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany

[9] Department of Neurology, Carl Von Ossietzky University, Oldenburg, Germany

[10] Berlin Institute of Health (BIH), Germany

[11] Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin

[12] Department of Neurology, Technical University of Munich, School of Medicine and Health, Klinikum rechts der Isar, München, Germany

[13] Department of Neurology, University Hospital, Otto-von-Guericke University Magdeburg, Magdeburg, Germany

[14] German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany

29 [15] German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany

30 [16] German Center for Mental Health (DZPG), partner site Berlin, Berlin, Germany

31 [17] German Centre for Cardiovascular Research (DZHK), Munich, Germany

32 [18] Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

33 [19] Program in Medical and Population Genetics and Cardiovascular Disease Initiative, Broad
34 Institute of MIT and Harvard, Cambridge, MA, USA

35

36 * These authors contributed equally to this study

37 [#] Names and affiliations of DEMDAS investigators are listed in the supplement (**Table S12**)

38

39 **Corresponding author**

40 Marios K. Georgakis, MD, PhD
41 Institute for Stroke and Dementia Research
42 Ludwig-Maximilians-University Hospital
43 Feodor-Lynen-Str. 17, 81377 Munich, Germany
44 Tel: +49-89-4400-46127, Fax: +49-89-4400-46040
45 E-mail: marios.georgakis@med.uni-muenchen.de

Abstract

Background and Objectives: Anti-inflammatory therapies are tested in randomized trials for secondary stroke prevention. Detecting inflammatory biomarkers that predict vascular recurrence could optimize patient selection for these trials.

Methods: In a multicenter prospective cohort study, we measured plasma levels of 22 inflammatory cytokines in 486 acute stroke patients (median age 68 years, 34% female, median 3 days post-stroke onset). Patients were followed for over 5 years through telephone and in-person interviews to record the occurrence of the following outcomes: (1) recurrent stroke or transient ischemic attack (TIA; primary outcome); (2) a composite of recurrent vascular events (stroke, TIA, acute coronary syndrome, hospital admission due to heart failure, and death; secondary outcome). Associations between cytokine levels and these outcomes were analyzed using Cox proportional hazards models adjusted for demographic and vascular risk factors.

Results: During the 5-year follow-up period, 59 patients (12.1%) experienced recurrent stroke or TIA, and 118 (24.3%) experienced recurrent vascular events. After adjustments for demographic and vascular risk factors, and correction for multiple comparisons, higher plasma levels of CD62E (adjusted Hazard Ratio [aHR] per SD increment: 1.686, 95%CI, 1.241–2.290) and MIF (aHR: 1. 627, 95%CI, 1.226–2.160) in the acute phase after stroke were statistically significantly associated with increased risk of recurrent stroke or TIA. The associations followed a dose-response pattern across quartiles of CD62E and MIF levels. Adding baseline CD62E and MIF levels to models including age, sex, vascular risk factors, and baseline C-reactive protein (CRP) levels led to significant improvements in the prediction of 5-year risk of recurrent stroke or TIA (ΔC-index 0.028 to 0.050).

Conclusion: Among stroke patients, higher baseline levels of CD62E and MIF improved prediction of 5-year risk of recurrent stroke or TIA on top of vascular risk factors and CRP levels. Whether assessment of these cytokines could improve patient selection for secondary prevention trials of anti-inflammatory treatments, should be explored in future studies.

Keywords: stroke; recurrence; inflammation; cytokines; risk prediction.

Introduction

Stroke is one of the leading causes of mortality and adult disability worldwide. In 2021, there were 93.8 million recorded prevalent strokes, accounting for 7.3 million deaths and 160.5 million disability-adjusted life-years globally.[1] Stroke prevalence is projected to increase from 3.9% to 6.4% among the US adult population, posing a major public health burden.[2] Despite advances in secondary prevention, stroke survivors face an alarmingly high risk of recurrent vascular events, with approximately 40% encountering a new stroke, acute coronary events, or cardiovascular death within 5 years.[3,4] These rates point to a high residual risk that current secondary prevention strategies fail to address.[5]

A growing body of evidence supports targeting inflammation as a potential strategy for secondary stroke prevention.[6–8] The central role of inflammation in the progression of atherosclerotic cardiovascular diseases[9] and stroke has been well documented through experimental research[10], genetic epidemiology[11,12], and vascular imaging studies[13,14]. Moreover, three phase 3 trials (CANTOS[15], LoDoCo2[16], COLCOT[17]) provided evidence that anti-inflammatory treatment with canakinumab or colchicine reduces vascular events in patients with coronary artery disease. Aiming to translate this concept to secondary stroke prevention, the recently completed CONVINCE study which testing the non-specific anti-inflammatory drug colchicine revealed no significant reduction in recurrent vascular events among patients with a recent non-disabling non-cardioembolic stroke.[8,18] However, notable risk reductions were observed in subgroups with atherosclerotic carotid stenosis or a history of coronary artery disease, underscoring the necessity for a more precise selection of patients who could benefit from anti-inflammatory therapies.

High-sensitivity C-reactive protein (CRP) and interleukin-6 (IL-6) are established inflammatory markers strongly associated with cardiovascular disease risk.[19,20] Both biomarkers have been previously associated with the risk of incident[21] and recurrent[22] stroke. CRP has also been used to select patients for inclusion in trials testing anti-inflammatory agents for cardiovascular disease.[15,23] However, their utility for secondary stroke prevention is debated due to high intra-patient variability, especially in the acute phase of stroke, and their lack of specificity for vascular inflammation.[24] Moreover, both proteins are acute-phase reactants, and their levels might increase as a result of infections or systemic inflammatory conditions.[25]

In order to improve risk stratification and optimize patient selection for anti-inflammatory secondary preventive strategies, it is essential to identify and validate new biomarkers.[26] Here, we investigated a comprehensive panel of cytokines, chemokines, and inflammatory adhesion

proteins as potential markers for risk of recurrent stroke and other vascular events following an incident stroke. Specifically, we measured the baseline circulating levels of these 22 mediators shortly after stroke in a multicenter prospective cohort study of 486 patients and explored associations with risk of recurrent stroke and recurrent vascular events over a follow-up period of 5 years.

Methods

Study Design and Baseline Assessments

Participants were drawn from the DEMDAS study (DZNE [German Center for Neurodegenerative Diseases] - Mechanisms of Dementia After Stroke), a multicenter, prospective cohort study conducted at six tertiary stroke centers in Germany. Details on the study's design, rationale, and baseline characteristics have been detailed elsewhere.[27,28]

In brief, DEMDAS recruited 600 patients aged 18 years or older who had experienced an acute stroke within the past five days and had no prior diagnosis of dementia. Exclusion criteria included severe comorbidities such as malignancies or end-stage renal disease, as well as the inability to provide consent. The recruitment period ran from May 2011 to January 2019. Participants underwent in-person follow-up assessments at 6-, 12-, 36-, and 60-months post-enrollment. This study adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.[29]

Participants underwent detailed interviews using standardized questionnaires and received clinical, cognitive, and laboratory evaluations. Baseline data collection included sociodemographic details, medical and family history, and medication use. Evaluations comprised physiological and anthropometric measurements including blood pressure and body mass index (BMI), and clinical assessments using tools like the National Institutes of Health Stroke Scale (NIHSS)[30], and stroke subtypes were classified according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria[31].

Standard Protocol Approvals and Patient Consent

The study was conducted in accordance with the Declaration of Helsinki and received ethical approval from institutional review boards of the participating sites. Primary ethics approval for the multicenter study was granted by the Ethics Committee of the Medical Faculty at LMU

Munich (201-13) and additional approvals were obtained from the Ethics Committee of the Medical Faculty at the University of Bonn (116/13), the Ethics Committee of the University Medical Center Göttingen (21/1/12), the Ethics Committee of the Technical University of Munich (93/14 S), and the Ethics Committee of Otto von Guericke University at the Medical Faculty and University Hospital Magdeburg (66/13). The Berlin study site (Charité – Universitätsmedizin Berlin) was covered by the ethics approval of the Medical Faculty of LMU Munich, according to Section 15 of the Berlin Medical Association Professional Code of Conduct (September 2009). Written informed consent was obtained from all participants or their legal representatives.

Blood Sample Collection and Processing

Blood samples for the current analysis were collected at baseline (within 5 days of stroke onset). The collection included one 9 mL Serum-Monovette for serum, three 9 mL EDTA-Monovettes (one specifically designated for plasma and two for DNA isolation), and one 2.5 mL Qiagen PAXGene tube for RNA-stabilized whole blood. Samples were processed immediately at each site and subsequently stored in a centralized biobank at the Institute for Stroke and Dementia Research (ISD) in Munich. Samples were centrifuged at 2,000 x g for 10 minutes at 15°C, aliquoted into 300 µL aliquots, and stored at -80°C. To minimize pre-analytical variability, rigorous quality control measures were implemented, including adherence to standard operating procedures and regular audits that have been previously described.[27] The specimens were double-pseudonymized and recorded using a protected data integration system to maintain confidentiality and traceability.

Cytokine Quantification and Quality Control

The Luminex® Procartaplex Multiplex Assay was used to quantify the levels of 22 cytokines in plasma baseline samples. The quantified cytokines included IP-10/CXCL10, MCP-1/CCL2, MIF, MIP-1α/CCL3, MIP-1β/CCL4, TNF-α, CD40L, CD62E/E-selectin, CD62P/P-selectin, CCL11, CSF-2, IFN-α, IFN-γ, IL-1α, IL-1β, IL-6, IL-4, IL-8/CXCL8, IL-10, IL-12p70, IL-13,and IL-17A. This panel was selected on the basis of previous evidence linking these cytokines to atherosclerosis and arterial inflammation.[32,33] Plasma samples were thawed, mixed thoroughly, and prepared for analysis according to the manufacturer's protocol. The Capture Bead Mix was vortexed for 30 seconds before adding 50 µL to each well of a 96-well plate. A

169 Hand-Held Magnetic Plate Washer ensured complete beads washing. Standards were prepared
170 using a 4-fold serial dilution to generate a standard curve for accurate quantification. Initial
171 tests determined that the optimal dilution factor for the plasma samples was 1:4, balancing
172 sensitivity with the assay's dynamic range. Plasma samples (25 μL) were added to the wells
173 containing the Capture Bead Mix and incubated on a shaker at 600 rpm for 2 hours at room
174 temperature. The plate was analyzed using the Luminex 200 machine, and the results were
175 processed using xPONENT v. 3.1 software (Luminex Corporation). The doublet discrimination
176 (DD) gate was set at 7,500-25,000, with a sample volume of 50 μL, and at least 50 events per
177 bead were recorded. A final reading volume of 120 μL per well was achieved by calibrating
178 the device to detect at least 50 beads per analyte per sample. The concentration of the analytes
179 was calculated using ProcartaPlex Analysis App software (Invitrogen) with a five-parameter
180 logistic (5PL) fitting model. Data were log-transformed and standardized by batch to minimize
181 between-batch variability, achieved by subtracting batch-specific means and dividing by batch-
182 specific SD of ln-transformed cytokine values. Intra-assay and inter-assay coefficients of
183 variation were monitored to ensure data reliability. Out-of-range (OOR) measurements below
184 the detection limit, accounting for 3.9% of the data, were assigned half the lowest detectable
185 concentration for each cytokine. Measurements exceeding 5 SD above or below the mean were
186 excluded as potential technical errors.

187

188 *Outcome Assessment and Follow-Up*

189 Follow-up assessments were conducted at 6, 12, 36, and up to 60 months and included clinical
190 evaluations, imaging, and medical record reviews by study physicians. The primary outcome
191 of the study was recurrent stroke or transient ischemic attack (TIA). Recurrent stroke was
192 defined as the acute onset of new neurological symptoms consistent with stroke and confirmed
193 by imaging (MRI or CT) as a new infarct or hemorrhage distinct from the initial event. TIA
194 was defined as the acute onset of neurological symptoms that resolved within 24 hours without
195 imaging evidence of a new infarction. The secondary composite outcome included recurrent
196 vascular events, defined as the occurrence of any of the following after the initial stroke:
197 myocardial infarction, angina pectoris, hospitalization due to acute or decompensated heart
198 failure, TIA, recurrent stroke, or all-cause mortality. All outcomes were confirmed by a
199 thorough inspection of the participants' medical records, review of imaging studies, and
200 clinical assessments during the in-person follow-up interviews by the study physicians. Deaths
201 from any cause were recorded throughout the follow-up period, with the cause determined

through medical record reviews and, when necessary, by contacting family members or caregivers, or accessing records from local registration offices.

Statistical Analyses

All statistical analyses were performed using R (version 4.3.3). The following R packages were utilized: *survival* package (version 3.7-0) for survival analysis, *survminer* package (version 0.4.9) for creating Kaplan-Meier curves, *survcomp* package (version 1.52.0) for C-index calculation, and *ggplot2* (version 3.5.1) for data visualization. Baseline characteristics for continuous variables were expressed as medians with interquartile ranges (IQR) and for categorical variables as counts and percentages. For group comparisons, the Mann–Whitney U or the Kruskal-Wallis tests were used for continuous variables, and the χ^2 or Fisher's exact tests were used for categorical variables.

The effects of potential determinants of cytokine levels were examined using univariable linear regression models for ln-transformed values of each cytokine. Each cytokine was modeled individually against each predictor variable to evaluate independent effects. Predictors included age, sex, BMI, low-density lipoprotein (LDL) cholesterol levels, hypertension, diabetes, history of atrial fibrillation, history of stroke, current smoking, current drinking, infarct volume, year of patient recruitment, NIHSS scores, time from symptom onset to blood collection, and CRP levels.

Cox proportional hazards regression models were employed to evaluate associations between cytokine levels and time-to-event outcomes, including primary outcomes of recurrent stroke/TIA and recurrent vascular events over a 5-year follow-up period. Ln-transformed cytokine levels were analyzed as both continuous (per SD increment) and categorical variables (split in quartiles). The associations between cytokine levels with the study outcomes were analyzed in two multivariable models adjusting for different sets of risk factors: (1) demographic factors (age, sex) and (2) demographic factors and baseline vascular factors (hypertension, diabetes, current smoking, history of stroke, history of atrial fibrillation, stroke subtypes, anticoagulants, antihypertensive medications, antiplatelet agents, statins, and LDL cholesterol).

To address the missing values in LDL cholesterol under the assumption of missing at random, we employed multiple imputation by chained equations (MICE) with predictive mean matching (PMM; five imputations, ten iterations) using the *mice* package (version 3.16.0) in

234 R.[34] The imputation model incorporated age, sex, hypertension, diabetes, current smoking,
235 history of stroke, statin medication use, and BMI to predict LDL cholesterol values. All Cox
236 regression models were executed separately within each imputed dataset. Subsequently,
237 regression coefficients and standard errors were pooled according to Rubin's Rules[35] to derive
238 combined adjusted hazard ratios (aHR), 95% confidence intervals (CI), and corresponding p-
239 values for each adjustment model. False discovery rate (FDR) correction was applied to control
240 for multiple comparisons in these analyses.

241 Sensitivity analyses were conducted to examine the robustness of the findings. Specifically,
242 analyses were repeated after excluding patients with hemorrhagic stroke (n=12) from the initial
243 study cohort, as well as after excluding TIA cases from the main outcomes. Kaplan-Meier
244 curves were generated to visualize time-to-events across different cytokine quartiles, and
245 differences between groups were compared using the log-rank test.

246 Model discrimination was assessed by calculating Harrell's C-index across all imputed datasets.
247 For each outcome, C-indices were pooled according to Rubin's rules[35] to account for both
248 within-imputation and between-imputation variance. Incremental discriminative value of
249 inflammatory biomarkers was evaluated by calculating ΔC-index between nested models, with
250 statistical significance determined using the *cindex.comp* function. Models were constructed
251 hierarchically, beginning with basic clinical variables (age and sex), followed by addition of
252 either CD62E, MIF, or both biomarkers simultaneously, with further adjustment for established
253 vascular risk factors and C-reactive protein.

254

255 **Results**

256 *Study flowchart and baseline characteristics*

257 DEMDAS recruited 600 participants. Due to limited reagent availability, plasma levels of 22
258 cytokines could only be quantified in a subset of the total study cohort. To ensure sufficient
259 longitudinal data for robust analysis, we prioritized participants who completed at least three
260 assessments during the 5-year follow-up (n=520). From this group, we randomly selected 491
261 participants for cytokine measurements, minimizing potential selection bias. Five participants
262 were excluded because more than 80% of their cytokine measurements were classified as
263 outliers, defined as values lower than 5 SD below the mean. As a result, 486 participants were
264 included in the final analysis (**Figure 1**). Their baseline characteristics are summarized in

265 **Table 1**. The baseline characteristics of included participants did not differ significantly from
266 those of participants who were not included in the analysis **(Supplementary Table S1)**. The
267 included participants had a median age of 68 years (IQR, 60-76 years) and 33.7% were female.
268 **Supplementary Table S2** provides an overview of the 22 cytokines measured in this study,
269 including their full names, abbreviations, and biological functions.

270



271

272 **Figure 1. Flowchart of the participants inclusion and exclusion criteria.**

273

274 *Determinants of baseline cytokine levels*

275 The distributions of ln-transformed, standardized values for the 22 quantified cytokines are
276 illustrated in **Supplementary Figure S1**. Most cytokines showed similar patterns of variation,
277 except for CD62E and MIF, which did not closely align with the patterns of other cytokines
278 (**Figure 2A**, **Supplementary Table S3**). The median time between stroke onset and blood
279 draw was 3.03 days (IQR 1.98–4.41 days) and more than 85% of the samples were fasting
280 samples collected in the morning. Univariable linear regression analyses showed that most
281 demographic, clinical, and technical factors had no significant associations with cytokine levels
282 (**Figure 2B**). Most importantly, technical factors, including time from symptom onset to blood
283 draw, as well as the year of patient recruitment (a proxy of the time that the sample remained
284 frozen before cytokine quantification) were not associated with plasma levels of any of the
285 cytokines (**Figure 2B**). Among vascular risk factors, we found a positive correlation between

CD62E levels and BMI (Spearman's $\rho = 0.25$, p-value < 0.001), as well as higher CD62E levels in patients with diabetes (**Figures 2B-D**). There were no significant differences in the levels of any of the 22 cytokines between male and female study participants (**Figure 2E, Supplementary Table S4**).



Figure 2. Correlations across cytokine levels and the effects of demographic, clinical, and technical factors on cytokine levels.
(A) Heatmap illustrating the Spearman correlations across the plasma levels of 22 cytokines in the DEMDAS cohort (N = 486). The color scale ranges from blue (negative correlation) to red (positive correlation). Significance is indicated by *p-value < .05, ** p-value < .01, and *** p-value < .001, representing false discovery rate (FDR) – corrected p-values for multiple comparisons. **(B)** Heatmap illustrating the effect estimates of demographic, clinical, and technical factors on ln-transformed standardized cytokine levels, as derived from univariable linear regression analyses. Red and blue colors represent positive and negative estimates, respectively, with statistical significance marked as in (A). **(C)** Violin plot illustrating the difference in plasma CD62E levels between patients with and without diabetes mellitus. The box represents the interquartile range (IQR; 25th to 75th percentiles), with the line inside the box representing the median. **(D)** Scatter plot illustrating the positive correlation between plasma CD62E levels and BMI. **(E)** Box plot illustrating comparisons in the sex-specific distribution of cytokine levels across the DEMDAS cohort. Each box represents IQR, covering the 25th to 75th percentiles of the data, with the line inside the box indicating the median value. The whiskers extend to the most extreme data points within 1.5 times the IQR. Abbreviations: BMI, body mass index, LDL, low density lipoprotein; NIHSS, National Institutes of Health Stroke Scale; IQR, interquartile range; FDR, false discovery rate.

Associations between cytokine levels and recurrent events

During the 5-year follow-up period, 59 (12.1%) participants experienced a recurrent stroke or TIA, and 118 (24.3%) participants experienced a composite of recurrent vascular events, including stroke, TIA, acute coronary syndrome, acute or decompensated heart failure, or death.

Figure 3 illustrates the aHR for the associations between the levels of the 22 cytokines (per SD increment in ln-transformed values) and recurrent stroke or TIA (**Figure 3A, Supplementary Table S5**) as well as recurrent vascular events (**Figure 3B, Supplementary Table S6**), derived from Cox regression analyses adjusted for age, sex, and vascular risk factors. Plasma levels of CD62E and MIF were associated with a higher risk of recurrent stroke or TIA over the 5-year follow-up period (FDR-adjusted p-value = 0.009) (**Figure 3A, Supplementary Table S5**). These associations remained significant when adjusting for age and sex (aHR for CD62E: 1.642 [95% CI, 1.244–2.168]; aHR for MIF: 1.586 [95% CI, 1.203–2.091]) and also when additionally adjusting for vascular risk factors (hypertension, diabetes, current smoking, history of stroke, history of atrial fibrillation, stroke subtypes, anticoagulants, antihypertensive medications, antiplatelet agents, statins, and low-density lipoprotein levels; aHR for CD62E: 1.686 [95% CI, 1.241–2.290]; aHR for MIF: 1.627 [95% CI, 1.226–2.160]). Although the associations between CD62E and MIF and recurrent vascular events also met the nominal threshold of p-value < 0.05, they were not significant after FDR correction (**Figure 3B**, **Supplementary Table S6**). Sensitivity analyses, excluding patients with hemorrhagic stroke (n = 12) at baseline (**Supplementary Figure S2, Supplementary Tables S7-S8**) and excluding TIA from the outcomes of interest (**Supplementary Figure S3, Supplementary Tables S9-S10**) yielded similar with consistent effects for both CD62E and MIF.



Figure 3. Associations of cytokine levels with recurrent stroke or transient ischemic attack (TIA) and recurrent vascular events (stroke, TIA, acute coronary syndrome, new onset of heart failure, or death) over the 5-year follow-up period.

Forest plots of hazard ratios (HR) for the associations of circulating baseline cytokine levels (per SD increment in ln-transformed values) with **(A)** recurrent stroke or TIA (n = 59) and **(B)** the composite endpoint of recurrent vascular events (n = 118) over the 5-year follow-up period. The HR in the first model (red) are adjusted for age and sex, while those in the second model (yellow) are further adjusted for vascular risk factors, including hypertension, diabetes, current smoking, history of stroke, history of atrial fibrillation, stroke subtypes, anticoagulants, antihypertensive medications, antiplatelet agents, statins, and low-density lipoprotein levels. Vertical error bars indicate the 95% CI for each HR. Significance is indicated by * p-value < .05, representing FDR-corrected p-values for multiple comparisons. Abbreviations: TIA, transient ischemic attack; HR, hazard ratio; CI, confidence interval; FDR, false discovery rate.

When analyzing by quartiles of the baseline CD62E and MIF distributions, dose dependent increases in the risk of recurrent stroke or TIA were observed for both proteins (**Figure 4**). Compared with the first quartile (Q1), patients in the highest quartiles of CD62E and MIF distributions (Q4) were at statistically significantly higher risk of recurrent stroke or TIA over the 5-year follow-up period (aHR for CD62E Q4 vs. Q1: 3.070 [95% CI, 1.384–6.812]; aHR for MIF Q4 vs. Q1: 2.636 [95% CI, 1.190–5.837]). These effects remained robust after adjusting for age, sex, and vascular risk factors, as well as when excluding TIA from the definition of the outcome (**Supplementary Figure S4**). For CD62E, similar albeit weaker associations were noted for the composite endpoint of recurrent vascular events (**Supplementary Figure S5**).



Figure 4. Dose-response associations of baseline CD62E and MIF levels with 5-year risk of recurrent stroke or transient ischemic attack (TIA).

(A) Kaplan-Meier 5-year recurrent stroke- or TIA-free survival curves for DEMDAS participants across quartiles (Q1 to Q4) of baseline circulating CD62E levels. **(B)** Forest plot of adjusted HR for recurrent stroke or TIA across quartiles of baseline circulating CD62E levels. **(C)** Kaplan-Meier 5-year recurrent stroke- or TIA-free survival curves for DEMDAS participants across quartiles (Q1 to Q4) of baseline circulating MIF levels. **(D)** Forest plot of adjusted HR for recurrent stroke or TIA across quartiles of baseline circulating MIF levels. In panels (B) and (D), the HR in the first model (red) are adjusted for age and sex, while the HR in the second model (yellow) are further adjusted for vascular risk factors, including hypertension, diabetes, current smoking, history of stroke, history of atrial fibrillation, stroke subtypes, anticoagulants, antihypertensive medications, antiplatelet agents, statins, and low-density lipoprotein levels. Horizontal lines represent the 95% CI for each HR. Statistical significance is indicated by *p-value < .05, **p-value < .01. Abbreviations: TIA, transient ischemic attack; HR, hazard ratio; CI, confidence interval.

Predictive performance of CD62E and MIF for recurrent events

As a final step, we assessed whether adding baseline CD62E and MIF levels to models including baseline demographic and vascular risk factors, as well as CRP levels, could improve

376 the prediction of recurrent stroke or TIA (**Table 2**). The addition of baseline CD62E and MIF
377 levels improved the C-index of Cox regression models for 5-year risk of recurrent stroke or
378 TIA on top of age and sex (ΔC-index = 0.050, p-value = 0.046), age, sex, and vascular risk
379 factors (ΔC-index = 0.033, p-value = 0.026), as well as age, sex, vascular risk factors, and
380 baseline CRP levels (ΔC-index = 0.028, p-value = 0.032). Similar improvements were
381 observed when analyzing 5-year risk of recurrent stroke, excluding TIA cases (**Supplementary**
382 **Table S11**).

383

384 **Discussion**

385 In this multicenter prospective cohort study of 486 acute stroke patients, we aimed to
386 comprehensively evaluate the predictive value of a panel of 22 cytokines for risk of vascular
387 recurrence. We found that higher baseline levels of CD62E and MIF were associated with an
388 increased risk of recurrent stroke or TIA over a 5-year follow-up period. The associations were
389 robust to adjustments for baseline demographic and vascular risk factors and followed dose-
390 response patterns. Adding baseline CD62E and MIF levels on top of age, sex, vascular risk
391 factors, and baseline CRP levels led to significant improvements in risk discrimination for
392 recurrent stroke or TIA (ΔC-index: 0.028 to 0.050).

393 Our findings may have important implications for risk stratification in stroke patients,
394 particularly in selecting candidates for anti-inflammatory treatments. In line with the CANTOS
395 trial[15], the ongoing ZEUS trial[23], which tests an anti-IL-6 antibody in a broad population with
396 atherosclerosis (including atherosclerotic stroke), uses a CRP threshold of >2 mg/dL to select
397 patients. Similarly, the CASPER trial, which tests colchicine in ischemic stroke patients,
398 restricts enrollment to those with CRP levels >2 mg/dL.[36] While a meta-analysis supports an
399 association between CRP levels and stroke recurrence,[22] CRP is not specific for arterial
400 inflammation, and transient increases in the acute phase after stroke could limit its utility for
401 risk stratification at that critical time window.[37] Here, we provide evidence that two other
402 inflammatory mediators, CD62E and MIF, may offer improved prediction of recurrent stroke
403 beyond traditional risk factors and CRP levels. Notably, the point estimates for the associations
404 between CD62E and MIF and recurrent stroke risk were larger than previously reported for
405 CRP (CD62E: HR for Q4 vs. Q1 3.070; MIF: HR for Q4 vs. Q1: 2.636; CRP: HR for Q4 vs.
406 Q1 1.40 when adjusting for age and sex).[22] Furthermore, in the largest meta-analysis to date,
407 the association of CRP with recurrent stroke was barely significant following adjustments for

408 vascular risk factors, whereas CD62E and MIF maintained significant associations with
409 recurrent stroke risk. While CD62E and MIF levels are known to be elevated in certain
410 infections, such as infective endocarditis and brucellosis,[38–40] their associations with recurrent
411 stroke in our study remained significant after adjusting for CRP, suggesting their predictive
412 value may extend beyond infection-related inflammation. Whether these biomarkers could aid
413 in selecting patients for anti-inflammatory treatments requires further investigation in external
414 cohorts and in *post hoc* analysis of randomized trial data. It is noteworthy, however, that despite
415 the significant association of the highest quartile (Q4) of MIF with recurrent stroke/TIA in
416 adjusted Cox models, the Kaplan–Meier analysis did not demonstrate statistically significant
417 differences among MIF quartiles (log-rank P = 0.177). This discrepancy could reflect limited
418 statistical power due to the moderate sample size and relatively lower event rate, emphasizing
419 the need for validation studies with larger cohorts to clarify the clinical utility of MIF
420 measurement.

421 Both CD62E and MIF have been extensively linked to the pathophysiology of vascular disease.
422 CD62E, an adhesion molecule also known as E-selectin, mediates leukocyte adhesion to the
423 endothelium, a critical step in the recruitment of immune cells to the subendothelial space and
424 the initiation of arterial inflammation.[41] As inflammation progresses, CD62E undergoes
425 increased shedding, making it detectable in plasma and reflecting its upregulation. This
426 shedding process, mediated by metalloproteinases such as ADAM17, has been shown to
427 regulate adhesion molecule function and contribute to inflammatory signaling pathways.[42–45]
428 Mouse studies have shown that targeting E-selectin reduces atherosclerotic lesions and
429 improves heart function.[46,47] In acute coronary syndrome, elevated CD62E levels reflect
430 endothelial activation, promoting leukocyte adhesion—a hallmark of inflammation and
431 vascular dysfunction.[47,48] While studies directly linking CD62E to stroke recurrence are limited,
432 it has been identified as a predictor of poor 3-month outcomes in stroke patients, including
433 functional impairment.[49] Experimental models further demonstrate that blocking E-selectin
434 improves cerebral blood flow and reduces infarct size, highlighting its therapeutic potential.[50]
435 Additionally, MR analyses have associated genetically proxied CD62E with adverse post-
436 stroke outcomes, reinforcing its role in cerebrovascular disease.[51] Similarly, MIF—a pro-
437 inflammatory cytokine and atypical chemokine[52], drives the atherogenic recruitment of
438 monocytes, neutrophils, T cells, and platelets to atherosclerotic plaques and has been
439 implicated in plaque instability and rupture.[53–56] Targeting MIF has been shown to reduce
440 atherosclerosis in experimental mouse models.[54,57–60] A study of 469 stroke patients with a

441 shorter follow-up (12 months) also found significant associations between baseline MIF levels
442 and risk of recurrent stroke.[61] In another study of stroke survivors, elevated MIF levels in the
443 acute phase after stroke were linked to poorer stroke outcomes.[62]

444 Our study has several limitations. First, cytokine levels were measured only once, shortly after
445 stroke onset, without assessing changes over time. Serial measurements could provide insights
446 into the temporal dynamics of inflammatory markers and their relationship with recurrence.
447 Second, despite our efforts, the DEMDAS cohort had a relatively high attrition rate of about
448 15% over the 5-year follow-up period, potentially leading to the selection of less severely
449 affected patients and an underestimation of recurrence rates. While this loss to follow-up could
450 introduce selection bias, baseline demographic and clinical characteristics of patients included
451 in and excluded from our analyses were similar. Third, the comprehensive follow-up protocol,
452 which included serial imaging and neuropsychological assessments, led to the preferential
453 recruitment of patients with milder strokes.[27,63] Although this might limit the generalizability
454 of our findings to a broader stroke population, these patients may represent a group that could
455 benefit from more aggressive secondary prevention including anti-inflammatory therapies.
456 Fourth, the relatively small number of recurrent vascular events — likely due to the mildly
457 affected stroke population — may have reduced statistical power to detect significant
458 associations with other promising cytokines after multiple testing corrections. Fifth, CRP levels
459 were missing in a substantial proportion of our study population (29%), further limiting
460 statistical power when comparing CD62E and MIF levels with CRP. Sixth, because of limited
461 data on the exact causes of death, our definition of recurrent vascular events included all-cause
462 mortality rather than only vascular death, deviating from the standard definition of major
463 adverse cardiovascular events.[64] However, since cardiovascular disease is the most common
464 cause of death among stroke survivors[65] and since there were only 46 deaths over the 5-year
465 follow-up period, we do not expect this to have introduced substantial misclassification bias.

466 In conclusion, our study demonstrates that elevated plasma levels of CD62E and MIF shortly
467 after acute stroke are associated with a higher 5-year risk of recurrent stroke or TIA, offering
468 improved predictive value on top of traditional risk factors and CRP levels. However, these
469 findings are preliminary and need to be confirmed through larger studies to establish their
470 clinical relevance. If validated in future studies, assessing these cytokines could enhance risk
471 stratification for stroke patients and inform patient selection for randomized trials of anti-
472 inflammatory agents.

473

Acknowledgements: We thank all patients for their study participation. We appreciate the support of Barbara Klapacz and Regina Altmann with data management and would like to thank Tatjana Wittenberg, Marion Sengewald, Sara Schmidt, Sandra Becker, Julia Schütte-Schmidt, Franziska Schulze, Christine Chahli, Esther D'Andrade, and Annette Eder for assistance with recruitment and data acquisition.

Funding: This work was supported by the FöFoLe program of LMU Munich (FöFoLe-Forschungsprojekt Reg.-Nr. 1120 to MKG), the Fritz-Thyssen Foundation (grant ref. 10.22.2.024MN to MKG), the German Research Foundation (DFG; Emmy Noether grant GZ: GE 3461/2-1, ID 512461526 to MKG; Munich Cluster for Systems Neurology EXC 2145 SyNergy, ID 390857198 to MKG and JB; CRC1123 projects A2 and A3 to JB), the Hertie Foundation (Hertie Network of Excellence in Clinical Neuroscience, ID P1230035 to MKG), the German Research Foundation (DFG) as part of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198, to MDi), and the Vascular Dementia Research Foundation. The DEMDAS study was funded by the German Center for Neurodegenerative Diseases. M.E. received funding from DFG under Germany´s Excellence Strategy – EXC-2049 – 390688087 and KFO-5023 project 2.

Conflicts of interest: JB is a co-inventor of patents covering anti-MIF strategies for inflammatory and cardiovascular diseases. ME reports grants from Bayer and fees paid to the Charité from Amgen, AstraZeneca, Bayer, BMS, Daiichi Sankyo, all outside the submitted work. MKG reports consulting fees from Tourmaline Bio, Inc. and GLG and involvement in the Editorial Board (Methodology and Biostatistics) of Neurology, all outside the scope of the submitted work. The remaining authors have nothing to declare.

References

1. Feigin VL, Abate MD, Abate YH, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Neurology. 2024;23:973–1003.
2. Joynt Maddox KE, Elkind MSV, Aparicio HJ, et al. Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050—Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association. Circulation. 2024;150:e65–e88.
3. Flach C, Muruet W, Wolfe CDA, et al. Risk and Secondary Prevention of Stroke Recurrence. Stroke. 2020;51:2435–2444.
4. Chen Y, Wright N, Guo Y, et al. Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0·5 million Chinese adults. The Lancet Global Health. 2020;8:e580–e590.
5. Hankey GJ. Secondary stroke prevention. The Lancet Neurology. 2014;13:178–194.
6. Ajala ON, Everett BM. Targeting Inflammation to Reduce Residual Cardiovascular Risk. Curr Atheroscler Rep. 2020;22:66.
7. Zietz A, Gorey S, Kelly PJ, Katan M, McCabe JJ. Targeting inflammation to reduce recurrent stroke. International Journal of Stroke. 2024;19:379–387.
8. Kelly P, Lemmens R, Weimar C, et al. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial. The Lancet. 2024;404:125–133.
9. Hansson GK, Hansson GK, Hansson GK, Hansson GK. Inflammation, Atherosclerosis, and Coronary Artery Disease. N Engl J Med. 2005;352:1685–1695.
10. Cao J, Roth S, Zhang S, et al. DNA-sensing inflammasomes cause recurrent atherosclerotic stroke. Nature. Epub 2024 Aug 7.:1–9.
11. Coveney S, Murphy S, Belton O, et al. Inflammatory cytokines, high-sensitivity C-reactive protein, and risk of one-year vascular events, death, and poor functional outcome after stroke and transient ischemic attack. International Journal of Stroke. 2022;17:163–171.
12. McPherson R, Davies RW, McPherson R, et al. Inflammation and Coronary Artery Disease: Insights From Genetic Studies. Canadian Journal of Cardiology. 2012;28:662–666.
13. Marnane M, Merwick A, Sheehan OC, et al. Carotid plaque inflammation on ^{18}F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Annals of Neurology. 2012;71:709–718.
14. McCabe JJ, Camps-Renom P, Giannotti N, et al. Carotid Plaque Inflammation Imaged by PET and Prediction of Recurrent Stroke at 5 Years. Neurology. 2021;97:e2282–e2291.
15. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377:1119–1131.
16. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383:1838–1847.
17. Tardif J-C, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381:2497–2505.
18. Fiolet ATL, Poorthuis MHF, Opstal TSJ, et al. Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials. eClinicalMedicine. 2024;76:102835.

19. Burger PM, Koudstaal S, Mosterd A, et al. C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular Disease. Journal of the American College of Cardiology. 2023;82:414–426.
20. Scirica BM, Morrow DA. The Verdict Is Still Out. Circulation. 2006;113:2128–2151.
21. Collaboration TERF. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. The Lancet. 2010;375:132–140.
22. McCabe JJ, Walsh C, Gorey S, et al. C-Reactive Protein, Interleukin-6, and Vascular Recurrence After Stroke: An Individual Participant Data Meta-Analysis. Stroke. 2023;54:1289–1299.
23. Novo Nordisk A/S. ZEUS - A research study to look at how Ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammation (ZEUS). ClinicalTrials.gov identifier: NCT05021835. Updated October 15, 2024. Accessed [cited 2024 Nov 12]. Available from: https://clinicaltrials.gov/study/NCT05021835
24. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med. 2008;359:2195–2207.
25. O'Donnell MA. Yaron Fuchs: Exploring the mysterious mixture of life and death. J Cell Biol. 2017;216:2600–2601.
26. Lindblad M, Unbeck M, Nilsson L, Schildmeijer K, Ekstedt M. Identifying no-harm incidents in home healthcare: a cohort study using trigger tool methodology. BMC Health Serv Res. 2020;20:289.
27. Georgakis MK, Fang R, Düring M, et al. Cerebral small vessel disease burden and cognitive and functional outcomes after stroke: A multicenter prospective cohort study. Alzheimer's & Dementia. 2023;19:1152–1163.
28. von Rennenberg R, Nolte CH, Liman TG, et al. High-Sensitivity Cardiac Troponin T and Cognitive Function Over 12 Months After Stroke—Results of the DEMDAS Study. Journal of the American Heart Association. 2024;13:e033439.
29. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. The Lancet. 2007;370:1453–1457.
30. Adams HP, Davis PH, Leira EC, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke. Neurology. 1999;53:126–126.
31. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41.
32. Sterpetti AV. Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications. Curr Atheroscler Rep. 2020;22:75.
33. Kong P, Cui Z-Y, Huang X-F, Zhang D-D, Guo R-J, Han M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022;7:131.
34. Buuren S van, Groothuis-Oudshoorn K. **mice**: Multivariate Imputation by Chained Equations in*R*. J Stat Soft. 2011;45:1–67.
35. Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol. 2009;9:57.
36. Australian New Zealand Clinical Trials Registry (ANZCTR). The effect of Colchicine on Cardiovascular Outcomes in Stroke Study (The CASPER Study).

596 ACTRN12621001408875. Updated October 20, 2021. Accessed [cited 2024 Nov
597 12];Available from:
598 https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382337&showOrigin
599 al=t rue&isReview=true.
600 37. Winbeck K, Poppert H, Etgen T, Conrad B, Sander D. Prognostic Relevance of Early
601 Serial C-Reactive Protein Measurements After First Ischemic Stroke. Stroke.
602 2002;33:2459–2464.
603 38. Sumaiya K, Langford D, Natarajaseenivasan K, et al. Macrophage migration inhibitory
604 factor (MIF): A multifaceted cytokine regulated by genetic and physiological strategies.
605 Pharmacology & Therapeutics. 2022;233:108024.
606 39. Ferrero MC, Bregante J, Delpino MV, et al. Proinflammatory response of human
607 endothelial cells to Brucella infection. Microbes and Infection. 2011;13:852–861.
608 40. Snipsøyr MG, Ludvigsen M, Petersen E, et al. A systematic review of biomarkers in the
609 diagnosis of infective endocarditis. International Journal of Cardiology. 2016;202:564–
610 570.
611 41. Munro JM. Endothelial-leukocyte adhesive interactions in inflammatory diseases. Eur
612 Heart J. 1993;14 Suppl K:72–77.
613 42. Reiss K, Ludwig A, Saftig P. Breaking up the tie: Disintegrin-like metalloproteinases as
614 regulators of cell migration in inflammation and invasion. Pharmacology &
615 Therapeutics. 2006;111:985–1006.
616 43. Garton KJ, Gough PJ, Philalay J, et al. Stimulated Shedding of Vascular Cell Adhesion
617 Molecule 1 (VCAM-1) Is Mediated by Tumor Necrosis Factor-α-converting Enzyme
618 (ADAM 17). Journal of Biological Chemistry. 2003;278:37459–37464.
619 44. THOMSON AW, SATOH S, NÜSSLER AK, et al. Circulating intercellular adhesion
620 molecule-1 (ICAM-1) in autoimmune liver disease and evidence for the production of
621 ICAM-1 by cytokine-stimulated human hepatocytes. Clinical and Experimental
622 Immunology. 2008;95:83–90.
623 45. Huber AR, Kunkel SL, Todd RF, et al. Regulation of Rransendothelial Neutrophil
624 Migration by Endogenous Interleukin-8. Science. 1991;254:99–102.
625 46. Tsoref O, Tyomkin D, Amit U, et al. E-selectin-targeted copolymer reduces
626 atherosclerotic lesions, adverse cardiac remodeling, and dysfunction. Journal of
627 Controlled Release. 2018;288:136–147.
628 47. Serebruany VL, Glassman AH, Malinin AI, et al. Enhanced platelet/endothelial
629 activation in depressed patients with acute coronary syndromes. Blood Coagulation &
630 Fibrinolysis. 2003;14:563–567.
631 48. Sarrafzadegan N, Sadeghi M, Ghaffarpasand F, et al. Interleukin-6 and E-selectin in
632 acute coronary syndromes and stable angina pectoris. Herz. 2012;37:926–930.
633 49. Richard S, Lagerstedt L, Burkhard PR, Debouverie M, Turck N, Sanchez J-C. E-selectin
634 and vascular cell adhesion molecule-1 as biomarkers of 3-month outcome in
635 cerebrovascular diseases. J Inflamm. 2015;12:61.
636 50. Huang J, Choudhri TF, Winfree CJ, et al. Postischemic Cerebrovascular E-Selectin
637 Expression Mediates Tissue Injury in Murine Stroke. Stroke. 2000;31:3047–3053.
638 51. Wang M, Zhang Z, Liu D, et al. Soluble adhesion molecules and functional outcome
639 after ischemic stroke: A Mendelian randomization study. Journal of Stroke and
640 Cerebrovascular Diseases. 2023;32:107136.
641 52. Calandra T, Roger T, Calandra T, Roger T. Macrophage migration inhibitory factor: a
642 regulator of innate immunity. Nat Rev Immunol. 2003;3:791–800.
643 53. Schober A, Bernhagen J, Thiele M, et al. Stabilization of Atherosclerotic Plaques by
644 Blockade of Macrophage Migration Inhibitory Factor After Vascular Injury in
645 Apolipoprotein E–Deficient Mice. Circulation. 2004;109:380–385.

646 54. Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine
647 receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13:587–596.
648 55. Asare Y, Schmitt M, Bernhagen J. The vascular biology of macrophage migration
649 inhibitory factor (MIF). Thromb Haemost. 2013;109:391–398.
650 56. Wirtz TH, Tillmann S, Strüßmann T, et al. Platelet-derived MIF: A novel platelet
651 chemokine with distinct recruitment properties. Atherosclerosis. 2015;239:1–10.
652 57. Burger-Kentischer A, Göbel H, Kleemann R, et al. Reduction of the aortic inflammatory
653 response in spontaneous atherosclerosis by blockade of macrophage migration
654 inhibitory factor (MIF). Atherosclerosis. 2006;184:28–38.
655 58. Verschuren L, Kooistra T, Bernhagen J, et al. MIF deficiency reduces chronic
656 inflammation in white adipose tissue and impairs the development of insulin resistance,
657 glucose intolerance, and associated atherosclerotic disease. Circulation Research.
658 2009;105:99–107.
659 59. Sinitski D, Kontos C, Krammer C, et al. Macrophage Migration Inhibitory Factor
660 (MIF)-Based Therapeutic Concepts in Atherosclerosis and Inflammation. Thromb
661 Haemost. 2019;119:553–566.
662 60. Kontos C, El Bounkari O, Krammer C, et al. Designed CXCR4 mimic acts as a soluble
663 chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting.
664 Nat Commun. 2020;11:5981.
665 61. Wang G, Li C, Liu Y, et al. Macrophage Migration Inhibitory Factor Levels Correlate
666 with Stroke Recurrence in Patients with Ischemic Stroke. Neurotox Res. 2019;36:1–11.
667 62. Wang C-W, Ma P-J, Wang Y-Y, et al. Serum level of macrophage migration inhibitory
668 factor predicts severity and prognosis in patients with ischemic stroke. Cytokine.
669 2019;115:8–12.
670 63. Fang R, Duering M, Bode FJ, et al. Risk factors and clinical significance of post-stroke
671 incident ischemic lesions. Alzheimer's & Dementia [online serial]. n/a. Accessed at:
672 https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14274. Accessed November
673 12, 2024.
674 64. Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse
675 cardiovascular event definitions used in observational analysis of administrative
676 databases: a systematic review. BMC Med Res Methodol. 2021;21:241.
677 65. Brønnum-Hansen H, Davidsen M, Thorvaldsen P. Long-Term Survival and Causes of
678 Death After Stroke. Stroke. American Heart Association; 2001;32:2131–2136.
679

680 **Tables**

681 **Table 1. Baseline characteristics of participants in the DEMDAS study included in the**
682 **current analysis.**

Baseline Characteristic	**Overall** **N = 486**
Age at recruitment (years), Median (Q1, Q3)	68.0 (60.0, 76.0)
Female sex, n (%)	164 (33.7%)
BMI (kg/m^2), Median (Q1, Q3)	26.5(24.3, 29.1)
LDL Cholesterol (mg/dL), Median (Q1, Q3)	124.0 (101.0, 151.6)
C-Reactive Protein (mg/dL), Median (Q1, Q3)	0.3 (0.1, 0.6)
(Missing)	135
NIHSS score at baseline, Median (Q1, Q3)	2 (1, 5)
Diabetes, n (%)	91 (19%)
Hypertension, n (%)	370 (76%)
Atrial fibrillation, n (%)	94 (19%)
Previous stroke, n (%)	49 (10%)
Current smoking, n (%)	123 (25%)
Current drinking, n (%)	363 (75%)
Stroke classification	
Ischemic stroke (TOAST subtypes), n (%)	
Large artery atherosclerosis	133 (27%)
Cardioembolism	105 (22%)
Small artery occlusion	57 (12%)
Other etiology	25 (5.1%)
Undefined etiology	154 (32%)
Hemorrhagic stroke	12 (2.5%)
Stroke lesion volume (mm^3), Median (Q1, Q3)	2,344 (512, 13,048)
(Missing)	18
Normalized stroke lesion volume %, Median (Q1, Q3)	0.2 (0.0, 0.8)
(Missing)	22

683 Abbreviations: BMI, body mass index; LDL, low-density lipoprotein; NIHSS, National
684 Institutes of Health Stroke Scale; TOAST, Trial of Org 10172 in Acute Stroke Treatment;
685 IQR, interquartile range.

686 **Table 2. C-index comparisons of predictive models for 5-year risk of recurrent stroke or**
687 **transient ischemic attack (TIA), incorporating different combinations of age, sex,**
688 **vascular risk factors (VRF; hypertension, diabetes, current smoking, history of stroke,**
689 **history of atrial fibrillation, stroke subtypes, anticoagulants, antihypertensive**
690 **medications, antiplatelet agents, statins, and LDL cholesterol), and baseline circulating**
691 **levels of C-reactive protein (CRP), CD62E, and MIF.**

Models	C-index	95% CI		ΔC-index	p-value
Age + Sex	0.616	0.544	0.687	ref	ref
Age + Sex + CD62E	0.661	0.593	0.729	0.045	0.067
Age + Sex + MIF	0.646	0.579	0.714	0.031	0.110
Age + Sex + CD62E + MIF	0.666	0.599	0.733	0.050	0.046
Age + Sex + VRF	0.685	0.625	0.744	ref	ref
Age + Sex + VRF + CD62E	0.712	0.652	0.772	0.027	0.052
Age + Sex + VRF + MIF	0.715	0.653	0.776	0.030	0.014
Age + Sex + VRF + CD62E + MIF	0.717	0.657	0.777	0.033	0.026
Age + Sex + VRF + CRP*	0.747	0.684	0.810	ref	ref
Age + Sex + VRF + CRP + CD62E*	0.768	0.704	0.831	0.020	0.085
Age + Sex + VRF + CRP + MIF*	0.770	0.706	0.834	0.023	0.032
Age + Sex + VRF + CRP + CD62E + MIF*	0.775	0.713	0.837	0.028	0.032

692 * Analysis restricted to 343 individuals with available C-reactive protein levels (41 recurrent
693 stroke or TIA events).
694 Abbreviations: TIA, transient ischemic attack; VRF, vascular risk factors; BMI, body mass
695 index; LDL, low-density lipoprotein; CRP, C-reactive protein; CI, confidence interval; ref,
696 reference.


600 participants were recruited for the DEMDAS study cohort.
Excluded
incomplete follow-up (did not complete at least 3 out of 5 follow-up visits) n = 80
Randomly excluded due to assay capacity limitations n = 29
491 participants underwent cytokine measurements.
Excluded
Cytokine measurements identified as statistical outliers (below 5 standard deviations from the mean) n = 5
486 participants with valid cytokine measurements were included in final analysis.


A
B
C
D
E
Correlation
Estimate
Age
Hypertension
Diabetes
History of atrial fibrillation
History of stroke
Current smoking
Current drinking
BMI
LDL cholesterol
Stroke lesion (%)
NIHSS score at baseline
Symptom to blood draw (Days)
Year of patient recruitment
p-value = 6.27e-05
Plasma CD62E levels (Z-scores)
Diabetes mellitus
No
Yes
R = 0.25
p - value = 2.7e-08
BMI (kg/m^2)
Plasma cytokine levels (Z-scores)
Male
Female


A
Recurrent stroke or TIA (59 events)
Hazard Ratio (HR)
2.5
2.0
1.5
1.0
0.5
*
**
*
**
CD40L
CD62E
CD62P
CCL11
CSF2
IFN-α
IFN-γ
IL-1α
IL-1β
IL-6
IL-4
IL-8
IL-10
IL-12p70
IL-13
IL-17A
IP-10
MCP-1
MIF
CCL3
CCL4
TNF-α
B
Composite endpoint of recurrent vascular events with TIA (118 events)
Hazard Ratio (HR)
2.0
1.5
1.0
0.5
CD40L
CD62E
CD62P
CCL11
CSF2
IFN-α
IFN-γ
IL-1α
IL-1β
IL-6
IL-4
IL-8
IL-10
IL-12p70
IL-13
IL-17A
IP-10
MCP-1
MIF
CCL3
CCL4
TNF-α
Adjusted for age and sex
Adjusted for age, sex, and vascular risk factors


A
CD62E Quartiles Q1 Q2 Q3 Q4
Recurrent Stroke/TIA−free Probability
1.00
0.95
0.90
0.85
0.80
0.75
Log−rank test: P = 0.024
0 1 2 3 4 5
Time (years)
Number at risk
CD62E Quartiles
122 113 106 96 84 61
121 109 102 97 83 58
121 102 89 79 75 54
122 97 87 76 72 55
0 1 2 3 4 5
Time (years)
C
MIF Quartiles Q1 Q2 Q3 Q4
Recurrent Stroke/TIA−free Probability
1.00
0.95
0.90
0.85
0.80
0.75
Log−rank test: P = 0.177
0 1 2 3 4 5
Time (years)
Number at risk
MIF Quartiles
122 108 100 92 80 63
121 106 97 85 79 55
121 107 94 85 75 57
122 100 93 86 80 53
0 1 2 3 4 5
Time (years)
B
Q1
1.000 (Ref)
1.000 (Ref)
Q2
1.146 (0.482-2.723)
1.236 (0.524-2.917)
Q3
1.534 (0.676-3.481)
1.643 (0.738-3.659)
Q4
** 3.070 (1.384-6.812)
** 2.906 (1.370-6.162)
0 1 2 3 4 5 6 7
Hazard Ratio (95% CI)
D
Q1
1.000 (Ref)
1.000 (Ref)
Q2
1.536 (0.661-3.571)
1.432 (0.635-3.230)
Q3
1.520 (0.656-3.524)
1.369 (0.607-3.085)
Q4
* 2.636 (1.190-5.837)
* 2.357 (1.102-5.043)
0 1 2 3 4 5 6
Hazard Ratio (95% CI)
Adjusted for age and sex
Adjusted for age, sex, and vascular risk factors